Despite a Moderna partnership that turned sour, AstraZeneca still wants a piece of the mRNA game. The British pharma company has signed a new mRNA manufacturing deal with China’s CanSino ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the ...

Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two that AstraZeneca dumped last year.. The Big ...

AstraZeneca is acquiring Icosavax, ... Pfizer and BioNTech have reached the clinic with an mRNA-based vaccine designed to protect against influenza and Covid-19.

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.

AstraZeneca’s shot was cheaper to make and easier to distribute than the mRNA shots… AstraZeneca is withdrawing its COVID-19 vaccine from the market because of low demand, the drugmaker said ...

AstraZeneca said on Wednesday a review of real-world data showed its COVID-19 vaccine provided equally effective protection against hospitalisation and death after two doses as with current mRNA ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.